In October 2019, ninety-four patients were admitted into Alexandria Poison Center (APC) with a history of ingestion of Feseekh (salted fish). In an attempt to allocate the resources, not all patients were given HBAT (botulism antitoxin heptavalent (A, B, C, D, E, F, G) equine immediately. The current study aimed to portray the clinical characteristics of the cases, explore the possible relation between these characteristics and necessity of HBAT administration, explore the reliability of mouse lethal test, and establish a clinical guide for management including preservation of resources. The current prospective study included 94 patients who were admitted to Alexandria Poison Center (APC) in the period from the 29th of September to the 27th of October 2019. The patients’ data were recorded using a checklist that includes: personal data, past medical history, clinical assessment, investigations, treatment, and the outcome. The checklist was carried out to assess and follow up each patient. Hospitalized patients were categorized according to symptoms consistent with botulism. The equine HBAT, made by Emergent BioSolutions Canada Inc. (formerly Cangene Corporation), was used in the treatment. HBAT was given to thirty-four patients (36.2%) only out of the total admission. However, eighty-two (87.2%) of patients were completely cured, whereas ten patients (10.6%) were discharged with mild neurological sequels and death occurred only in two cases (2.2%). Sixty cases (63.8%) with suspected foodborne botulism could be managed by supportive treatment only with no need for HBAT, while patients with evident neurological signs received HBAT immediately.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Anderson DM, Kumar VR, Arper DL, Kruger E, Bilir SP, Richardson JS (2019) Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product. PLoS One 14(11): e0224700.
Barker D, Gillum KT, Niemuth NA, Kodihalli S (2019) Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs. PLoS One 14(9): e0222670.
Chaudhry R. (2011) Botulism: A Diagnostic Challenge. Indian J Med Res 134(1):10-2.
Fagan RP, Neil KP, Sasich R, Luquez C, Asaad H, Maslanka S et al. (2011) Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. Clin Infect Dis 53(9): e125-e128.
Fleck-Derderian S, Shankar M, Rao AK, Chatham-Stephens K, Adjei S, Sobel J et al. (2017) The epidemiology of foodborne botulism outbreaks: a systematic review. Clin Infect Dis 66(suppl_1): S73-S81. DOI: https://doi.org/10.1093/cid/cix846.
Gaware VM, Kotade KB, Dolas RT, Dhamak KB, Somawanshi SB, Nikam VK (2011) Botulism foodborne disease: a review. J Chem Pharm Res 3(1):84-92.
Gottlieb SL, Kretsinger K, Tarkhashvili N, Chakvetadze N, Chokheli M, Chubinidze M, Hoekstra RM, Jhorjholiani E, Mirtskhulava M, Moistsrapishvili M, Sikharulidze M, Zardiashvili T, Imnadze P, Sobel J (2007) Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis 45 (2): 174-80.
Kongsaengdao S, Samintarapanya K, Rusmeechan S, Wongsa A, Pothirat C, Permpikul C, Pongpakdee S, Puavilai W, Kateruttanakul P, Phengtham U, Panjapornpon K, Janma J, Piyavechviratana K, Sithinamsuwan P, Deesomchok A, Tongyoo S, Vilaichone W, Boonyapisit K, Mayotarn S, Piya-Isragul B, Rattanaphon A, Intalapaporn P, Dusitanond P, Harnsomburana P, Laowittawas W, Chairangsaris P, Suwantamee J, Wongmek W, Ratanarat R, Poompichate A, Panyadilok H, Sutcharitchan N, Chuesuwan A, Oranrigsupau P, Sutthapas C, Tanprawate S, Lorsuwansiri J, Phattana N, Thai Botulism Study Group (2006) Thai Botulism Study Group. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis 43:1247–56.
Lindstrom M, Korkeala H (2006) Laboratory diagnostics of botulism. Clin Microbiol Rev 19(2):298-314. https://doi.org/10.1128/CMR.19.2.298-314.2006
O'Horo JC, Harper EP, El Rafei A, Ali R, DeSimone DC, Sakusic A et al. (2017) Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923-2016. Clin Infect Dis 66(suppl_1): S43-S56.
Pisanti R, Vitiello R, Formicola S, Pisanti A (2009) Infant botulism mimicking an acute abdomen. Infez Med 17 (4): 254-6.
Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T (2020) Safety, and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis 70(9):1950-1957. https://doi.org/10.1093/cid/ciz515.
Schussler E, Sobel J, Hsu J, Yu P, Meaney-Delman M, Grammer LC et al. (2017) Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); And the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. Clin Infect Dis 66 (suppl_1): S65-S72.
Sheth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, Doerr F, Juliao P, Gonzalez G, Burnett C, Drenzek C, Shuler C, Austin J, Ellis A, Maslanka S, Sobel J (2008) International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 47:1245–51.
Sobel J. (2009) Diagnosis and treatment of botulism: a century later, clinical suspicion remains the cornerstone. Clin Infect Dis 48:1674–75.
Spini RG, Ferraris V, Glasman MP, Orofino G, Casanovas A, Debaisi G (2015) Intussusception in infant with diagnostic botulism: a case report. Arch Argent Pediatr 113(5): e286-9. https://doi.org/10.5546/aap.2015.e286.
Veterinarians warn of the mass death of fish in Lake Rashid (2019)
Weber JT, Hibbs RG Jr, Darwish A, Mishu B, Corwin AL, Rakha M, Hatheway CL, Sharkawy SE, Rahim SAE, al Hamd MFS, Sarn JE, Blake PA, Tauxe RV (1993) A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis 167(2):451-4. https://doi.org/10.1093/infdis/167.2.451.
Wheeler C, Inami G, Mohle-Boetani J, Vugia D (2009) Sensitivity of mouse bioassay in clinical wound botulism. Clin Infect Dis 48(12):1669-73. https://doi.org/10.1086/599029.
Wilder-Kofie TD, Lúquez C, Adler M, Dykes JK, Coleman JD, Maslanka SE (2011) An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comp Med 61(3):235-42.
Yu P. (2015) Heptavalent botulinum antitoxin (BAT) use in patients treated under CDC’s expanded access IND, 2010–2013. Atlanta: CDC
Availability of data and materials
The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.
Ethics approval and consent to participate
Approval was obtained from the Research Ethics Committee of Faculty of Medicine, Alexandria University (IRB NO:00012098, FWA NO: 00018699, serial protocol NO:0304565).
Adherence to national and international regulations
The Ethics Committee is constituted and operates according to ICH GCP Guidelines and applicable local and institutional regulations and guidelines that govern ethics committees’ operation.
Consent for publication
Not applicable as the research didn’t include any individual person’s data in any form.
The authors declare no competing interests.
Responsible Editor: Lotfi Aleya
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ghitani, S.A., Ghanem, M.A., Sultan, E.A. et al. Outbreak of foodborne botulism in Alexandria, Egypt: modulating indications for administration of heptavalent botulinum antitoxin. Environ Sci Pollut Res 28, 61547–61553 (2021). https://doi.org/10.1007/s11356-021-14909-z
- Heptavalent botulinum antitoxin